Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara and Novo Nordisk’s Novolog. The Trump administration announced in August ...
The US Health Resources and Services Administration (HRSA) revealed the initial nine drugs to be included in the 340B rebate model. The decision comes after pharma companies filed suit in regard to ...
Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback